Shijiazhuang, Hebei, China The company was established in Asia in China. The main office of represented Corporate Investor is situated in the Shijiazhuang.
The standard case for the fund is to invest in rounds with 7 partakers. The meaningful sponsors for the fund in investment in the same round are Yingke Capital, TF Capital, Sinopharm Capital.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2018.
Among the most popular fund investment industries, there are Health Care, Medical. Among the various public portfolio startups of the fund, we may underline Haihe Biopharma, GenFleet Therapeutics Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China.
| Fund Name | Location |
| Ameritas Life Insurance | Lincoln, Nebraska, United States |
| Canadian Glycomics Network | - |
| Enron Ventures | - |
| Ges.co.srl | - |
| GrainInnovate | Australia, New South Wales, Sydney |
| GS Capital | China, Shanghai |
| Intelectium Ventures | Community of Madrid, Madrid, Spain |
| Invictus Growth Partners | California, San Francisco, United States |
| Lynx Asia Partners | Central, Central Region, Singapore |
| Northwestern Mutual Life | Milwaukee, United States, Wisconsin |
| Olbia Invest | France, Provence-Alpes-Côte d'Azur, Provence-Alpes-Cote d'Azur |
| Oriza Seed Capital (Oriza Yuandian) | China, Jiangsu, Suzhou |
| Psion | Canada, Mississauga, Ontario |
| sopoong | Seoul, Seoul-t'ukpyolsi, South Korea |
| SRF Partners Group | - |
| Sustainable Technologies Fund | Stockholm, Stockholm County, Sweden |
| ThinkEquity Partners | California, San Francisco, United States |
| Villgro Kenya | - |
| Yunmu Capital | - |
| Zhejiang Huamei Jincheng Wenhua Chanye Touzi Guanli Co., Ltd | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Haihe Biopharma | $185M | 24 Jul 2020 | Shanghai, China | ||
Haihe Biopharma | $146M | 11 Feb 2019 | China, Shanghai | ||
GenFleet Therapeutics | $17M | 30 Nov 2018 | Shanghai, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Haihe Biopharma | $185M | 24 Jul 2020 | Shanghai, China | ||
Haihe Biopharma | $146M | 11 Feb 2019 | China, Shanghai | ||
GenFleet Therapeutics | $17M | 30 Nov 2018 | Shanghai, China |
